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Abstract: Advances in high-throughput technologies and its implementation worldwide have had
a considerable impact on the elucidation of the molecular causes underlying neurodevelopmental
psychiatric disorders, especially for autism spectrum disorder and intellectual disability (ID). Never-
theless, etiology remains elusive in close to 50% of cases, even in those families with multiple affected
individuals, strongly hinting at a genetic cause. Here we present a case report of two siblings affected
with severe ID and other comorbidities, who embarked on a genetic testing odyssey until diagnosis
was reached by using whole genome sequencing (WGS). WGS identified a maternally inherited
novel missense variant (NM_031466.7:c.1037G > A; p.Gly346Glu) and a paternally inherited 90 kb
intragenic deletion in TRAPPC9 gene. This report demonstrates the clinical utility of WGS in patients
who remain undiagnosed after whole exome sequencing.
Keywords: TRAPPC9; whole genome sequencing; neurodevelopmental disorders; neuropsychiatric
disorders; compound heterozygous mutations; missense mutation; structural variants
1. Introduction
Neurodevelopmental psychiatric disorders, including autism spectrum disorder
(ASD), intellectual disability (ID), epilepsy, and schizophrenia (SZ), are a group of hetero-
geneous disorders associated mainly with the disruption of the tightly coordinated events
that lead to brain development [1]. This process results from highly complex and coor-
dinated activity involving genetic and environmental processes. This group of disorders
constitutes a serious health problem in our society, accounting as a group for one of the
top 30 leading contributors to overall disease burden, as measured by global disability
adjusted life years [2].
Neurodevelopmental disorders (NDDs) are associated with a sex bias, with a male:female
ratio of 2:1 existing among individuals with ID and a 4:1 ratio for individuals with ASD [3].
NDDs are clinically heterogeneous, with overlapping symptoms, and frequently co-occur,
suggesting a common genetic etiology; this explains the high degree of comorbidity among
them [4]. Much like their phenotypes, the genetic etiology underlying NDDs is highly
heterogeneous, with varying degrees of genetic overlap and penetrance, or expressivity,
across phenotypes. Many studies have suggested shared molecular pathways for ID and
other NDDs. This has been inspired by the high comorbidity that is commonly observed
between ID and other cognitive impairments such as ASD and epilepsy [5]. Insights from
“The Psychiatric Cell Map Initiative” have evidenced three main molecular pathways
involved in these disorders: protein synthesis, transcriptional or epigenetic regulation and
synaptic signaling [6,7].
Genes 2021, 12, 557. https://doi.org/10.3390/genes12040557 https://www.mdpi.com/journal/genes
Genes 2021, 12, 557 2 of 8
Advances in high-throughput technologies and their implementation worldwide have
had a considerable impact on elucidating the molecular causes underlying NDDs, especially
for ID and ASD [5]. The introduction of whole exome sequencing (WES) into medical
practice has transformed the diagnosis and management of patients with genetic disease.
Nevertheless, etiology remains elusive in close to 50% of NDD cases, even in those families
with multiple affected individuals, strongly hinting at a genetic cause. A step forward
is whole genome sequencing (WGS), which delivers a base-by-base view of all genomic
alterations, including single nucleotide variants (SNV), insertions and deletions, copy
number variations (CNVs) and structural variations (SVs). The combination of emerging
short-read and long-range genome sequencing has greatly improved the identification of
this last type of genetic variation. SV represents the greatest source of genetic diversity in
the human genome [8]. Therefore, it is not surprising that both de novo and inherited SVs
are frequently linked to the pathogenesis of NDDs such as ASD, ID, SZ and developmental
delay. However, the overall contribution of SV effects in disease etiology is still unclear [9].
Here we present a case report of a two siblings affected with severe ID and other
comorbidities, who embarked on a genetic testing odyssey of more than ten years before
diagnosis was reached by applying WGS with two distinct analysis pipelines.
2. Material and Methods
2.1. Case Report
The family consisted of two affected siblings and a non-affected daughter born from
a non-consanguineous Spanish family. This family was referred in 2007 to the Clinical
Genetics consultation of the Hospital Clinic of Barcelona (Barcelona, Spain). Both siblings
were characterized by severe ID, absent speech, behavioral abnormalities such as “happy
disposition”, slight obesity and mild facial dysmorphism with mild myopia (Figure 1).
Brain magnetic resonance imaging showed dysgenesis of the corpus callosum and cisterna
magna. Standard karyotyping, CGG repeat expansion in FMR1 gene, MLPA (Salsa P036
and P070, MRC-Holland, Amsterdam, The Netherlands), array-CGH (4 × 44K, Agilent
Technologies, Santa Clara, CA, USA) and WES testing were normal (Agilent’s V3 capture
kit, Agilent Technologies, and sequenced on a HiSeq™ 2000 Sequencing System, Illumina,
San Diego, CA, USA).
Figure 1. Images of patients carrying heterozygous mutation in TRAPPC9 gene.
All individuals provided written consent, and the study was approved by the Institu-
tional Review Boards of the Hospital Clinic of Barcelona.
2.2. Whole Genome Sequencing and Data Analysis
WGS was performed to individual II.2 in Macrogen Inc. (Macrogen, Seoul, Korea)
as a part of a research project (COHORTES/Programa de Enfermedades Raras No Diag-
nosticadas). Data analysis was performed in the Genome Diagnostics Nijmegen of the
Radboud University Medical Center (Nijmegen, The Netherlands). Alignment against
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the GRCh37 human reference genome was performed with a Burrows-Wheeler Aligner
(BWA) v.0.7.8 [10]. PCR duplicates were marked using Samtools v.1.5. [11] Variant call-
ing was carried out using xAtlas v.0.1 and variants were annotated using an in-house
developed pipeline. This variant annotation was performed using the Variant Effect
Predictor (VEP V.91) [12] and Gencode V.34lift37 basic gene annotations. Frequency infor-
mation was added from GnomAD V.2.1.1. Allelic variants with frequency >0.01 in any of
the databases used (GnomAD (https://gnomad.broadinstitute.org/; accessed on 21 July
2018), ExAC (http://exac.broadinstitute.org/; accessed on 21 July 2018) and 1000Genomes
(https://www.internationalgenome.org/; accessed on 21 July 2018)) were discarded. Data
analysis was focused on missense, nonsense, frameshift, and small insertion/deletion
variants. CNVs were called using Control-FREEC v9.1 [13]. SVs were called using Manta
Structural Variant Caller V.1.1.0 (Illumina), which uses a paired end and split read evidence
approach for SV identification [14]. SVs and CNVs were annotated using an in-house devel-
oped pipeline. This pipeline was based on ANNOVAR and Gencode V.34lift37 basic gene
annotations. Additional frequency information was added from GnomAD V.2.1, 1000G V.8
and GoNL SV release 1 databases.
2.3. Segregation Studies
Segregation analyses of Trafficking protein particle complex 9 (TRAPPC9) variants were
performed in available relatives. Segregation of the SNV was performed by Sanger se-
quencing. PCR primers were designed using the Primer3 Input version 4.0.0 web tool
(http://primer3.ut.ee/; accessed on 23 August 2018). PCR products were directly se-
quenced using the BigDye® Terminator version 3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA). The reaction was run in an ABI Prism 3100XL automated
sequencer (Applied Biosystems, Foster City, CA, USA) and the results were analyzed
with SEQUENCE® Pilot version 4.0.1 software (JSI medical systemsCorp, New York, NY,
USA). Segregation of the SV was performed using a high resolution CGH-microarray (60K)
following the manufacturer’s recommendations (qGenomics, Barcelona, Spain). Data was
analyzed with the qGenviewer Software v2.1.1 (qGenomics).
3. Results
Genetic investigation performed prior to WGS failed to identify the genetic alter-
ation explaining the disease in this family. Following the guideline recommendations for
the study of ID in 2007, the application of conventional karyotype, analysis for fragile X
syndrome and subtelomeric rearrangements did not identify pathogenic variants in the
affected individuals. After CGH microarray implementation, CNVs were discarded by
microarrayCGH (44K). In addition, WES was performed on both siblings as previously
described [15]. Data analysis of the variants shared by both patients evidenced the pres-
ence of a novel missense variant in heterozygosis in TRAPPC9 gene (NM_031466.7; chr8
(GRCh37): g.141445327 C > T; c.1037G > A; p.Gly346Glu). This variant was not present in
the public databases and was predicted to be deleterious by nine different programs. At this
time, pathogenic variants in TRAPPC9 gene were exclusively associated to consanguineous
families with homozygous loss-of-function (LOF) variants. Since no second mutation was
found on the other TRAPPC9 allele, and CNVs were previously discarded by array-CGH
(44K), this variant was finally classified as a variant of unknown significance (VUS). Next,
WGS was performed on individual II.2, and genetic diagnosis was reached combining two
WGS data analysis pipelines: the one used for calling SNVs and indels variants and the one
used for calling SV. The first pipeline confirmed the presence of the previously detected
variant in TRAPPC9 gene (Figure 2a), and data analysis for SV detected a novel 90 kb
intragenic deletion spanning from exon 8 and 9 in TRAPPC9 gene (Figure 2b). Although
this was a novel deletion, intragenic deletions of TRAPPC9 gene were recently described as
pathogenic variants as detected in six patients with ID [16]. The deletion was confirmed by
a higher resolution microarrayCGH (60K), and the breakpoints of the SV were redefined to
arr[GRCh37] arr8q24.3(141313791_141403956) × 1 (Figure 2b).
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Figure 2. Molecular analysis of TRAPPC9 mutations and segregation analyses. (a) Upper: view of the missense variant in
heterozygosity in TRAPPC9 gene in the Integrative Genome Viewer; lower: validation of the variant by Sanger sequencing.
(b) Upper: screenshot of the Integrative Genome Viewer showing the structural variant in heterozygosity (red square)
removing exons 8 and 9 in TRAPPC9 (blue boxes in the bottom). Note the decreased coverage in the deleted region (red
vertical arrows). The size of the alteration does not allow for capturing of the whole deletion; lower: validation of the
intragenic deletion by microarrayCGH (60K). (c) Pedigree of the family and results of segregation analysis. Affected
individuals are shown as shaded squares.
The clinical presentation of the patients was compatible with the OMIM description
of an autosomal recessive ID disorder mapping to the short arm of chromosome 8 (Mental
retardation autosomal recessive 13; OMIM # 613192), and molecular analysis of relatives
verified the segregation of these variants with the disease in the family. Sanger sequencing
revealed that the missense variant was maternally inherited, and microarrayCGH identified
the intragenic deletion in the father. The unaffected sister did not present any of the
identified variants (Figure 2c).
4. Discussion
Mutations in TRAPP proteins have been collectively termed “TRAPPopathies” [17].
TRAPPC9 gene encodes a subunit of the trafficking protein particle II (TRAPPII), one out of
three TRAPP complexes that act as multimeric guanine nucleotide exchange factors (GEFs)
to activate certain GTPases, helping regulate vesicular trafficking between organelles. The
TRAPP complex acts as an activator of a subgroup of Ypt/RAB GTPases required for
secretion and macroautophagy/autophagy. TRAPP subunits are conserved from yeast to
human cells and have been largely implicated in human disease [18].
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TRAPPC9, also known as NIK-and-IKK2-binding protein (NIBP), is extensively ex-
pressed in the nervous system and plays a role in regulating neurogenesis and neuronal
differentiation. It plays a role in both the regulation of protein trafficking and the neuronal
NF-kB signaling pathway [19,20]. In the former, TRAPPC9 is involved in the trafficking of
cargo from the endoplasmic reticulum to the Golgi; interestingly, impairment of vesicular
trafficking has been observed as a common biologic defect in neurologic disorders [19].
In addition, TRAPPC9 is involved in the activation of NFkB, which remains sequestered
in the cytoplasm while is not activated [20]. The NFkB signaling pathway is involved in
the regulation of many different cellular pathways, including memory, neurogenesis, and
synaptic plasticity [21]. Although the mechanisms underlying how the loss of TRAPPC9
impairs brain development and function are yet to be defined, it is that possible these
two roles for TRAPPC9 might contribute to neuronal impairment. In this regard, Ke and
collaborators (2020) recently reported a Trappc9 knock-out mouse that recapitulated features
of human ID [22]. They demonstrated in the mouse model that Trappc9 deficiency impairs
learning and memory by causing imbalance of dopamine D1 and D2 neurons [22].
In humans, pathogenic variants in TRAPPC9 gene are associated with a nonsyndromic
form of ID named “Mental retardation, autosomal recessive 13” (OMIM # 613192), although
recurrent brain abnormalities and obesity are commonly observed in some patients. The
delineation of the phenotype was made based on multiplex consanguineous families from
different ethnic backgrounds that carried homozygous LOF variants, including frameshift,
nonsense and splicing mutations as well as intragenic deletions and duplications. To date,
only three families with compound heterozygous disease LOF variants have been reported
(Figure 3). In 2018, Mortreux and collaborators reported the first two non-consanguineous
families who were compound heterozygotes for an intragenic CNV and a LOF variant [16].
Shortly after, a novel compound heterozygous family was reported harboring a frameshift
variant and a splice site mutation (c.3349 + 1G > A) [23]. A recently report found a non-
consanguineous family with a paternal LOF frameshift variant and a maternal complex
allele with a missense c.1705T > C (p.Ser569Pro) and a frameshift variant (c.1708dupC,
p.Arg570Profs*80) [24]. However, this maternal allele certainly corresponds to an indel mu-
tation c.1705delinsCC (p.Ser569ProfsTer81) instead of a complex allele. To our knowledge,
there is only one pathogenic homozygous missense variant associated with this syndrome.
The pathogenic missense c.533T > C (p.Leu178Pro) variant was identified in two siblings
with severe ID, microcephaly and hypoplasia of the corpus callosum [25]. Here, we report
for the first time a non-consanguineous family with compound heterozygous mutation
consisting of a novel missense variant and an intragenic deletion in TRAPPC9 gene. The
missense mutation p.Gly346Glu identified in our family is located in the Trs120 region of
the TRAPPC9 protein (Figure 3), which is considered a relevant region for the stability
of TRAPP complexes [26]. This report extends the mutational spectrum of TRAPPC9
mutations since, irrespective of the type of disease causing the variant, all patients are
characterized by severe ID, behavioral abnormalities, absent speech and white matter
abnormalities.
Furthermore, genetic alteration of TRAPPC9 gene has not only been associated with
ID but also with SZ [27] and attention deficit/hyperactivity disorder [28], and it is currently
considered as a strong candidate risk gene for ASD by The Simons Foundation Autism
Research Initiative (https://gene.sfari.org/database/human-gene/TRAPPC9; accessed on
1 March 2021). It has recently been suggested that heterozygous LOF of TRAPPC9 might
be a risk factor for ASD, which would be further exacerbated in cases with homozygous or
compound heterozygous mutations [20].
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Figure 3. Summary of reported TRAPPC9 mutations. Graphical representation of TRAPPC9 protein based on the longest
isoform that encodes for 1246 amino acids (ENST00000389328.4/NM_031466). All mutations were previously reported in
homozygous changes, except for three heterozygous changes, which are presented in italics.
5. Conclusions
In the last years, WES has emerged as a comprehensive and cost-effective approach
to identify pathogenic variants in the protein-coding regions of the genome. However,
the high percentage of undiagnosed cases in NDDs suggests that there is a large number
of disease causing variants that are not being captured by the current approaches. This
scenario might be comparable to the parable of the Blind Men and the Elephant, trying
to reconstruct the complexity of human disease through fragmented experience; thus, we
argue that WGS offers a promising alternative for undiagnosed patients.
For many years, the cost of sequencing an entire genome remained prohibitively
expensive for routine use in clinical practice. However the significant decline in sequencing
costs will lead to the implementation of WGS as a single genetic test to reliably identify
and characterize the comprehensive spectrum of genetic variation, thus increasing the
diagnostic yield of patients affected with a neurodevelopmental/neuropsychiatric disorder.
Although the characterization of functional non-coding variants remains challenging,
efforts should be focused on the most well-known relevant regulatory regions, including the
3′ and 5′ untranslated regions and the putative noncoding regulatory DNA corresponding
to promoters and enhancers and the transcription factor-binding sites [29–31]. However,
our report supports the fact that the greatest advantage of WGS is the more accurate
detection of CNV and SV rather than the discovery of disease causing variants in non-
coding regions of the human genome. Notwithstanding that the implementation of WGS
in routine genetic diagnosis is still challenging, this report demonstrates the clinical utility
of WGS for individuals in whom WES fails to identify a pathogenic variant.
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